Other

Pharmacia Corporation

G.d. Searle & Company

Charles A McWherter

Yiqing Feng

Nicholas R Staten

John Patrick McKearn

Barbara Kure Klein

Linda L Zurfluh

S Christopher Bauer

Maire Helena Caparon

Judith G Giri

Stephen C Lee

Charles M Baum

Philip R Streeter

Susan L Woulfe

Nancy I Minster

John P Mc Kearn

John C Minnerly

Neena L Summers

Sarah Ruth Braford-Goldberg

Neena Summers

Yiping Feng

Disclosed are novel multi-functional chimeric hematopoietic receptor agonist proteins, DNAs which encode the multi-functional chimeric hematopoietic receptor agonist proteins, methods of making the multi-functional chimeric hematopoietic receptor agonist proetiens and methods of using the multi-functional chimeric hematopoietic receptor agonist proteins.

Multi-functional chimeric hematopoietic receptor agonists

Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

Fused G-CSF and IL-3 proteins and uses thereof

Disclosed are novel flt-3 receptor agonist proteins, DNAs which encode the flt-3 receptor agonist proteins, methods of making the flt-3 receptor agonist proteins and methods of using the flt-3 receptor agonist proteins.

Circular permuteins of flt3 ligand

Disclosed are novel G-CSF receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

G-CSF receptor agonists

Multi-functional hematopoietic fusion proteins between sequence

The present invention is drawn to human stem cell factor receptor agonist polypeptides, nucleic acid molecules encoding same, methods of producing the agonist polypeptides from the nucleic acid sequences and therapeutic compositions comprising the agonist polypeptides. The polypeptides of the instant invention are derived from the sequnce of SEQ ID NO:1, wherein 1-23 amino acids are optionally deleted from the C-terminus and the N-terminus is joined to the C-terminus, either directly or through a linker and C- and N-termini are created between an amino acid pair chosen from 23-24 through 110-111 of SEQ ID NO:1, generating said human stem cell factor receptor agonist polypeptide. The human stem cell factor receptor agonist polypeptide may additionally be immediately be preceded by a (methionine.sup.-1), (alanine.sup.-1) or (methionine.sup.-2, alanine.sup.-1).

Stem cell factor receptor agonists

Growing community of inventors

Wildwood, MO, United States of America

Charles A McWherter